SEC 13F Intelligence

Managers / Q3 2019 · view latest →

VHCP Management II, LLC

CIK 0001602263 · 7 BRYANT PARK, 23RD FLOOR, NEW YORK, NY, 10018 · 650 475 3734

Reported Value
$262M
Q3 2019
Positions
21
Filings on Record
4
2019–present window
Filed
Nov 13, 2019
original filing

Summary

Vhcp Management II, LLC reported $262M in U.S.-listed holdings across 21 positions for Q3 2019.

The portfolio is heavily concentrated: TXG alone accounts for 34.3% of reported value.

Compared with Q2 2019, the fund opened 3 new positions and exited 3.

Portfolio Metrics

Turnover
+31.2%
vs prior filed quarter
Top-10 Concentration
+88.8%
share of reported value
Largest Position
+34.3%
10x Genomics
New / Exited
3 / 3
positions this quarter

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded, with multiple share classes and repeated sub-manager rows for the same issuer combined into one position — the same rule the holdings table uses by default. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q1 ’19: $342MQ1 ’19Q2 ’19: $317MQ2 ’19Q3 ’19: $262MQ3 ’19Q4 ’19: $379MQ4 ’19filingsflow.com

Portfolio Composition

By security type
Common Stock: 79.8%Other: 20.2%
  • Common Stock · 79.8% · $209M
  • Other · 20.2% · $53M

Quarter-over-Quarter Changes full breakdown →

vs Q2 2019 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
TXG10X Genomics Inc.NEW+1.79M1.79M+$90M$90M
Radius Health IncNEW+13.7K13.7K+$352,000$352,000
Prevail Therapeutics IncNEW+2.6K2.6K+$32,000$32,000
ZogenixSOLD OUT−362.0K0−$17M$0
KDMNKadmon Holdings Inc.SOLD OUT−249.5K0−$514,000$0
Gemphire TherapeuticsSOLD OUT−471.5K0−$382,000$0
Marinus Pharmaceuticals IncADDED+742.8K1.49M−$798,000$2M
Tricida IncTRIMMED−309.8K118.9K−$13M$4M

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q3 2019

21 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1TXG10X Genomics Inc.history →COM34.31%$90M1.79M
2Biohaven PharmaceuticalsCOM11.33%$30M712.9K
3ASNDAscendis Pharma A/Shistory →COM8.61%$23M234.6K
4Shockwave Medical IncCOM7.37%$19M646.4K
5Obseva SACOM7.15%$19M2.25M
6AXSMAxsome Therapeutics Inchistory →COM6.89%$18M892.9K
7Ra PharmaceuticalsCOM6.10%$16M677.2K
8BCRXBioCryst Pharmaceuticals Inchistory →COM3.14%$8M2.87M
9PTGXProtagonist Therapeutics Inchistory →COM1.95%$5M426.8K
10SPROSpero Therapeutics Inchistory →COM1.91%$5M474.0K
11CNSTConstellation Pharmaceuticalshistory →COM1.79%$5M726.7K
12Kiniksa Pharmaceuticals LtdCOM1.75%$5M540.5K
13LJPCLa Jolla Pharmaceuticalshistory →COM1.74%$5M518.1K
14Kalvista PharmaceuticalsCOM1.67%$4M376.9K
15Tricida IncCOM1.40%$4M118.9K
16MISTMilestone Pharmaceuticals Inchistory →COM1.06%$3M148.6K
17Marinus Pharmaceuticals IncCOM0.87%$2M1.49M
18Bellerophon TherapeuticsCOM0.76%$2M4.15M
19Radius Health IncCOM0.13%$352,00013.7K
20Proteostasis Therapeutics IncCOM0.04%$110,000130.7K
21Prevail Therapeutics IncCOM0.01%$32,0002.6K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q4 2019$379M20Feb 13, 202013F-HRchanges · EDGAR ↗
Q3 2019$262M21Nov 13, 201913F-HRchanges · EDGAR ↗
Q2 2019$317M21Aug 13, 201913F-HRchanges · EDGAR ↗
Q1 2019$342M21May 14, 201913F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.